• Kyrok

  Participated · Seed · Jun 2026

  Kyrok provides an AI operating system designed to sit on top of existing ERP systems and unify supply chain workflows for pharmaceutical and chemical SMEs. Its platform uses industry-specific AI agents that guide workflows, capture operational knowledge over time, and reduce the need for costly system migrations. The company’s first product module targets customer service teams to support order intake and industry-specific workflows, with planned future modules for production planning, material planning and procurement. Kyrok was founded in 2025 and is based in Berlin. Several SMEs are piloting the platform and the company reports the system captures over 80% of complex orders without errors while lowering error rates and freeing employee time on routine tasks. Kyrok plans to use recent pre-seed funding to develop the operating system further, expand module offerings and grow its team in response to market demand.

• Mirantus Health

  Participated · Seed · Nov 2025

  Mirantus Health digitises and decentralises ophthalmic pre-screenings through its software platform “mira,” which equips optician shops to capture retina images, intra-ocular pressure, slit-lamp photos, refraction data and visual-acuity tests. The data are transmitted to a pool of ophthalmologists who return a written assessment within 24–48 hours, flagging any abnormalities that warrant a full medical examination. The company already serves more than 200 locations across Germany and supports scheduling through a network of over 400 partner ophthalmologists, relieving pressure on traditional practices. By 2027 Mirantus aims to scale the service to more than 1,000 sites throughout Germany, Austria and Switzerland. The solution targets growing shortages in eye-care caused by an ageing specialist workforce, with roughly 30 % of German ophthalmologists nearing retirement. Revenue metrics were not disclosed, but the firm will use fresh capital to expand geographically and enhance its software. Its value proposition centres on early detection, reduced wait times for patients and lower long-term costs for the healthcare system.

• StratifAI

  Participated · Equity · Oct 2025

  StratifAI is a precision oncology company founded in Berlin that applies artificial intelligence to identify prognostic and predictive biomarkers from multimodal clinical data. Its core product, the Polaris™ platform, fuses H&E histology with RNA-Seq gene expression to link spatial tumor signals directly to patient outcomes, speeding up biomarker discovery while lowering associated costs. The company is assembling a large multimodal reference dataset from collected tumor samples to continually expand its portfolio of spatial biomarkers. StratifAI’s first commercial test, Polaris™ Breast, assesses metastasis risk in early breast cancer and is currently undergoing regulatory review in the EU and the United States. Fresh capital is earmarked to complete clinical validation of Polaris™ Breast and to establish a scalable regulatory framework for clinical AI diagnostics. In parallel, the firm is deepening collaborations with oncology centers and pharmaceutical partners to build the clinical evidence required for guideline inclusion and routine practice. By leveraging growing digital pathology data, StratifAI aims to unlock a sizable, under-served market in cancer diagnostics and deliver more individualized and equitable care for patients with solid tumors.

• deepeye

  Participated · Seed · Nov 2023

  Deepeye Medical builds an AI-based software platform that analyzes 3D eye tomography to generate data-driven, personalized treatment suggestions for age-related macular degeneration (AMD). Its algorithm was trained on hundreds of thousands of retinal scans and aims to assess disease activity and progression to help optimize therapy intervals and support patient education. The software is intended to complement clinical expertise and provide a one-click, patient-oriented therapy decision aid by 2024. The company reports collaborations with major pharmaceutical firms including Novartis, Bayer and Roche and is used by companies and physicians to gain insights from therapy data. Deepeye Medical was founded in 2021 and is based in Munich/Landshut. Financially, the company has secured investor funding plus research and development grants to further develop its platform.

• faCellitate

  Participated · Seed · Sep 2022

  faCellitate develops an intelligent, ultra-low attachment polymer surface coating platform for plastic and glassware, with an initial commercial product (BIOFLOAT™ 96-well plate) targeting reproducible 3D cell culture. The coating platform supports chemistry-driven surface modification and applications such as cell- and protein-repellent surfaces and biospecific surfaces under the BIOINSTRUCT™ brand. The company was formed at Chemovator (BASF’s internal venture builder) and was spun off at the end of 2021; it is based in Mannheim with labs in Heidelberg. faCellitate reports one product already on the market with positive customer feedback and is rolling out further plate formats and new product lines. Management says the company will leverage cross-selling opportunities and expand its product pipeline over the next 12–24 months. The team is led by co‑founder and CEO Dr. Simon Widmaier.

No current team members are available.